Alizyme has a late stage, diversified portfolio of competitive products for the treatment of obesity and type 2 diabetes, ulcerative colitis and mucositis.

Share Price

04 Jul 09
London Stock Exchange

2.94 GBp

Change +0.14

(20 minutes delayed)


Corporate Presentations

23/03/09
Preliminary Results webcast for the year ended 31 December 2008

23/03/09
Preliminary Results Presentation for the 12 months ended 31 December 2008

Latest News

02/07/09
Change of date of Annual General Meeting

29/06/09
Trading Update

23/06/09
BOARD CHANGE